# Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

> **NCT00084565** · PHASE2 · WITHDRAWN · sponsor: **Fox Chase Cancer Center**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** estramustine phosphate sodium
- **DRUG:** paclitaxel
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00084565
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2003-11
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never activated at Fox Chase Cancer Center.
- **Last updated:** 2013-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084565, "Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00084565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*